Braidwell LP Buys New Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Braidwell LP purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 515,726 shares of the company’s stock, valued at approximately $12,640,000. Braidwell LP owned about 42.69% of Oruka Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FMR LLC acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at about $114,763,000. Great Point Partners LLC acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth approximately $12,614,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth approximately $1,037,000. 56.44% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ORKA shares. Leerink Partners assumed coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Leerink Partnrs upgraded shares of Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Stock Up 8.4 %

NASDAQ ORKA opened at $20.26 on Friday. Oruka Therapeutics, Inc. has a 52-week low of $18.20 and a 52-week high of $53.88. The business’s 50-day moving average is $25.67.

Oruka Therapeutics Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.